<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691078</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0214</org_study_id>
    <nct_id>NCT02691078</nct_id>
  </id_info>
  <brief_title>Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors</brief_title>
  <official_title>Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Financiadora de Estudos e Projetos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto do Cérebro do Rio Grande do Sul - InsCer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the properties of the image capture test using 99m Tc - HYNIC -TOC EDDA
      (octreotide labeled with 99mTc) for the diagnosis of neuroendocrine tumors compared to the
      111In - DTPA-octreotide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the images captured with 99m Tc - HYNIC -TOC EDDA ( octreotide labeled with 99mTc ) and 111In - DTPA-octreotide for the diagnosis of neurocrine tumors</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visualization of the ocurrence of the neuroendocrine tumor lesions with both radiopharmaceutical agents</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of neuroendocrine tumor lesions visualized with both radiopharmaceutical agents</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Adult patients with neuroendocrine tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide</intervention_name>
    <description>The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals</description>
    <arm_group_label>Adult patients with neuroendocrine tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histological diagnosis of neuroendocrine tumors

          -  Patients with indication for the staging exam with 11In

          -  Patients diagnosed in any tumor stage

          -  Patients with &gt; 18 years

          -  Male and female patients

          -  Patients not receiving somatostatin analogues for at least 1 month before image
             capturing

        Exclusion Criteria:

          -  Pregnant women

          -  Patients with previous tumor resection of the primary tumor without metastatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Voelcker</last_name>
    <phone>55 51 3384 5334</phone>
    <email>laura.voelcker@lacog.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raíra Maschmann</last_name>
    <phone>55 51 3384 5334</phone>
    <email>raira.maschmann@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto do Cérebro do Rio Grande do Sul</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Moriguchi, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol. 2013 Dec;24(12):3040-4. doi: 10.1093/annonc/mdt377. Epub 2013 Sep 19.</citation>
    <PMID>24050954</PMID>
  </reference>
  <reference>
    <citation>Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma): current concepts. Hematol Oncol Clin North Am. 2007 Jun;21(3):395-407; vii. Review.</citation>
    <PMID>17548031</PMID>
  </reference>
  <reference>
    <citation>Pinchot SN, Holen K, Sippel RS, Chen H. Carcinoid tumors. Oncologist. 2008 Dec;13(12):1255-69. doi: 10.1634/theoncologist.2008-0207. Epub 2008 Dec 17. Review.</citation>
    <PMID>19091780</PMID>
  </reference>
  <reference>
    <citation>Rust E, Hubele F, Marzano E, Goichot B, Pessaux P, Kurtz JE, Imperiale A. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging. 2012 May 21;12:173-84. doi: 10.1102/1470-7330.2012.0026. Review.</citation>
    <PMID>22743056</PMID>
  </reference>
  <reference>
    <citation>Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006 Jul;36(3):228-47. Review.</citation>
    <PMID>16762613</PMID>
  </reference>
  <reference>
    <citation>Frilling A, Akerström G, Falconi M, Pavel M, Ramos J, Kidd M, Modlin IM. Neuroendocrine tumor disease: an evolving landscape. Endocr Relat Cancer. 2012 Sep 14;19(5):R163-85. doi: 10.1530/ERC-12-0024. Print 2012 Oct. Review.</citation>
    <PMID>22645227</PMID>
  </reference>
  <reference>
    <citation>Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005 May;128(6):1717-51. Review.</citation>
    <PMID>15887161</PMID>
  </reference>
  <reference>
    <citation>Dierdorf SF. Carcinoid tumor and carcinoid syndrome. Curr Opin Anaesthesiol. 2003 Jun;16(3):343-7.</citation>
    <PMID>17021482</PMID>
  </reference>
  <reference>
    <citation>Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005 Dec;19(12):1610-2. Epub 2005 Oct 5.</citation>
    <PMID>16211437</PMID>
  </reference>
  <reference>
    <citation>Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004 Jul;151(1):15-27. Review.</citation>
    <PMID>15248818</PMID>
  </reference>
  <reference>
    <citation>Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004 Jun;25(3):458-511. Review.</citation>
    <PMID>15180952</PMID>
  </reference>
  <reference>
    <citation>Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide. Eur J Nucl Med. 2000 Jun;27(6):628-37.</citation>
    <PMID>10901448</PMID>
  </reference>
  <reference>
    <citation>Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000 Sep;27(9):1318-25.</citation>
    <PMID>11007513</PMID>
  </reference>
  <reference>
    <citation>Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med. 2003 May;44(5):708-16.</citation>
    <PMID>12732671</PMID>
  </reference>
  <reference>
    <citation>Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):69-85. Review.</citation>
    <PMID>17382266</PMID>
  </reference>
  <reference>
    <citation>Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993 Aug;20(8):716-31. Review.</citation>
    <PMID>8404961</PMID>
  </reference>
  <reference>
    <citation>Lamberts SW, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol. 1993 Jan;14(1):27-55. Review.</citation>
    <PMID>8097480</PMID>
  </reference>
  <reference>
    <citation>Lamberts SW, Reubi JC, Krenning EP. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors. Acta Oncol. 1993;32(2):167-70. Review.</citation>
    <PMID>8391830</PMID>
  </reference>
  <reference>
    <citation>Öberg K. Gallium-68 somatostatin receptor PET/CT: is it time to replace (111)Indium DTPA octreotide for patients with neuroendocrine tumors? Endocrine. 2012 Aug;42(1):3-4. doi: 10.1007/s12020-012-9681-4.</citation>
    <PMID>22562721</PMID>
  </reference>
  <reference>
    <citation>Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001 Jul;28(7):836-46. Erratum in: Eur J Nucl Med 2001 Sep;28(9):1433.</citation>
    <PMID>11504080</PMID>
  </reference>
  <reference>
    <citation>Jones SR, Carley S, Harrison M. An introduction to power and sample size estimation. Emerg Med J. 2003 Sep;20(5):453-8. Review. Erratum in: Emerg Med J. 2004 Jan;21(1):126.</citation>
    <PMID>12954688</PMID>
  </reference>
  <reference>
    <citation>Silberstein EB, Ryan J. Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine. J Nucl Med. 1996 Jan;37(1):185-92. Erratum in: J Nucl Med 1996 Jun;37(6):1064-7.</citation>
    <PMID>8543992</PMID>
  </reference>
  <reference>
    <citation>Vallabhajosula, S. Molecular Imaging: radiopharmaceuticals for PET and SPECT. New York: Springer, 2009. 371p</citation>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>EDDA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

